Glycemic outcomes, insulin, and system use
INTERACTIONS
The time spent in AHCL, CGM use, and CGM outcomes for the 24-h day and percentage of time spent at SG ranges during the nighttime, for each age group during MM780G+G4S use are shown (Glycemic outcomes during pediatric and adult pivotal trial CAS use and real-world use of the MiniMed™ 780G system with Guardian™ 4 Sensor. CAS, continued access study.Daily Insulin Delivered and System Interactions During Pivotal Trial Continued Access Study and Real-World Use of the MiniMed™ 780G System with Guardian™ 4 SensorData are shown as mean ± SD.System-initiated insulin included programmed open-loop basal rates, Auto Basal and Auto Correction.AHCL, advanced hybrid closed loop; BGM, blood glucose measurement; CAS, continued access study; SD, standard deviation; TDD, total daily dose of insulin.